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Abstract
Background: Acute myeloid leukaemia (AML) with nucleophosmin-1 (NPM1) mutation is a major subtype of AML.
The NPM1 mutation induces a myeloproliferative disorder, but evidence indicates that other insults are necessary
for the development of AML. We utilised microRNA microarrays and functional assays to determine if microRNA
dysregulation could be involved in the pathogenesis of in NPM1 mutated (NPM1
mut)-AML.
Results: We used a stringent locked nucleic acid (LNA) based microRNA microarray platform to profile bone
marrow samples of patients with normal karyotype AML. A panel of five microRNAs dichotomised AML patients
according to their NPM1 mutational status. miR-10a, let-7b and let-7c were significantly over-expressed, while miR-
130a and miR-335 were under-expressed in NPM1
mut-AML when compared to NPM1
wildtype-AML. Of these, miR-10a
is the most differentially expressed in NPM1
mut-AML versus NPM1
wildtype-AML (> 10 fold higher as confirmed by
qRT-PCR). To investigate the functions of miR-10a, the OCI-AML3 cell line was utilised, which is the only
commercially available cell line bearing NPM1
mut. OCI-AML3 cells were firstly demonstrated to have a similarly high
miR-10a expression to primary NPM1
mut-AML patient samples. Inhibition of miR-10a expression by miRCURY LNA
Inhibitors (Exiqon) in these cells resulted in increased cell death as assessed by MTS, cell cycle and Annexin-V
assays and reduced clonogenic capacity, indicative of an involvement in leukaemic cell survival. In silico filtering of
bioinformatically predicted targets of miR-10a identified a number of potential mRNA targets with annotated
functions in haematopoiesis, cell growth and apoptosis. Lucferase reporter assays confirmed a number of these
putative tumorogenic genes that are miR-10a suppressible including KLF4 and RB1CC1. This provides a potential
mechanism for the pathogenic role of miR-10a in NPM1
mut-AML.
Conclusions: This study provides, for the first time, in vitro evidence of a pro-survival role of miR-10a in NPM1
mut-
AML, that it may contribute to the pathogenesis of NPM1
mut-AML and identifies putative tumorogenic targets.
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Background
Acute myeloid leukaemia (AML) represents the conver-
gent outcome a number of genetic abnormalities that
have consequence in crucial cellular pathways of haema-
topoiesis. With an increasing knowledge of cellular pro-
cesses and an accompanying improvement in our ability
to interrogate these pathways, a spectrum of recurrent
genetic abnormalities relevant to AML has become
increasingly apparent. While most AML cases have at
least one detectable genetic mutation potentially respon-
sible for their pathogenesis, there remains a significant
minority in which no abnormality is detectable [1].
MicroRNA-mediated post-transcriptional control of
gene expression is a relatively newly discovered mechan-
ism of cellular regulation that could account for some of
the gaps in our knowledge of AML pathogenesis [2].
Through their repressive action on complementary sites
in 3’ untranslated regions (3’UTR) of target genes [2],
these short 19-25 nucleotide RNA species are important
in numerous processes including haematopoietic stem
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myeloid differentiation [5-7], cell cycle and proliferation
[8,9], apoptosis [10,11] and gene methylation [12]. All of
these pathways are of potential relevance to AML
pathogenesis if dysregulated.
NPM1-mutated AML (NPM1
mut-AML) accounts for
approximately 30% of cases of adult AML (and up to
60% of AML with normal karyotype) [13]. Recently
NPM1
mut activation has been found to initiate a myelo-
proliferative disorder after knock-in into mouse haema-
topoietic stem cells, however co-expression with a
secondary mutation was proposed to be needed for
overt AML development [14]. Global microRNA expres-
sion was assayed in a cohort of normal karyotype AML
(NK-AML) using a stringent LNA-based microarray
platform. We showed that among other differentially
expressed microRNAs miR-10a, but not miR-10b, was
significantly markedly over-expressed in NPM1
mut-AML
versus AML not bearing NPM1 gene insertions
(NPM1
WT-AML). It is also demonstrated that the only
available NPM1 mutated cell line, OCI-AML3, exhibits
high miR-10a expression. We have demonstrated that
knockdown of over-expressed miR-10a in these cells
resulted in reduced cellular survival and clonogenic
growth. Using luciferase reporter analysis, we confirmed
several miR-10a suppressible target genes located in key
cellular pathways of significance to AML. Together,
these findings suggest miR-10a may provide a pro-survi-
val signal contributing to the pathogenesis of NPM1
mut-
AML.
Results
microRNA profiling of AML samples by NPM1 mutational
status
Analysis of microRNA expression of NK-AML samples
demonstrated a clear pattern of clustered expression
according to NPM1 mutational status, with three micro-
RNAs over-expressed in NPM1
mut-AML (miR-10a, let-
7b and let-7c) and two microRNAs under-expressed
(miR-130a and miR-335) (Figure 1A and 1B).
Furthermore, miR-10a was the most over-expressed
microRNA with a FC of 19.6 as compared to normal
bone marrow (Additional file 1: Table S1). miR-10a was
13.4 fold over-expressed in NPM1
mut-AML compared to
NPM1
WT-AML samples, indicative of the potential
importance of miR-10a in NPM1
mut-AML (Figure 1B).
In comparison for miR-10b (whose sequence only differs
f r o mm i R - 1 0 ab yas i n g l eb a s ep a i r ) ,t h em a g n i t u d eo f
the FC was only 1.4. Further to this, the expression of
ratio of miR-10a to miR-10b in the NPM1
mut samples
was 53:1. This indicates that miR-10a and not miR-10b
is the dominantly expressed gene in NPM1
mut-AML.
qRT-PCR was used to confirm that miR-10a expres-
sion is significantly higher in the NPM1
mut-AML group
compared to both NPM1
WT-AML and normal BM sam-
ples (mean FC values of 79.9, 7.0 and 1.0 respectively)
(Figure 1C). Thus while there was some overlap of miR-
10a expression between NPM1
mut and NPM1
WT-AML
samples, high levels of miR-10a expression were very
specific for NPM1
mut -AML. miR-10a expression was
not significantly DE between normal bone marrow and
NPM1
WT-AML.
Inhibition of miR-10a expression by antisense LNA
oligonucleotides
miR-10a was expressed at higher levels in OCI-AML3
cells than other myelomonocytic leukeamic cell lines
(Figure 1D). These results indicate that OCI-AML3 cells
recapitulate the miR-10a expression of their parental
primary leukaemic sample and may therefore serve as a
useful model for study of miR-10a over-expression and
its relationship with the NPM1 mutation.
Transfection of OCI-AML3 cells with anti-miR-10a
LNA resulted in knockdown of miR-10a expression as
assessed by qRT-PCR and by reporter assay (Additional
file 2: Figure S1). As determined by MTS assay, inhibi-
tion of miR-10a resulted in significant reduction in cell
Figure 1 Unique microRNA signature of NPM1
mut AML is
characterised by miR-10a over-expression. A Hierarchical cluster
analysis of 28 AML samples according to NPM1 mutational status,
with over-expression of miR-10a, let-7b, let-7c and under-expression
of miR-130a and miR-335, with accompanying fold change B. C
Validation of miR-10a expression by qRT-PCR in normal bone
marrow, NPM1
wt-AML and NPM1
mut-AML respectively, with values
presented normalised to the mean of the normal bone marrow
samples. D miR-10a expression by qRT-PCR in selected malignant
cell lines: MV4-11, OCI-AML3 (myelomonoblastic) and THP-1
(monoblastic). The expression values are depicted relative to that of
MV4-11 cells, which had the lowest miR-10a expression. Error bars
denote SEM. *p < 0.05 by Unpaired Two-tailed T-test.
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with a non-targeting LNA (Figure 2A).
miR-10a knockdown resulted in increased proportions
of Annexin-V positive events compared to control trea-
ted cells by 34.9% and 39.3% at 24 and 48 h respectively,
indicating increased cell death (Figure 2C, n = 4).
Furthermore, knockdown of miR-10a resulted in a
29.4% increase in the number of cells in the sub-G1
fraction of the cell cycle (Figure 2D, n = 4) also indicat-
ing an increase in cell death. Caspase-3 activation was
not detected in the assays analysed in response to miR-
10a knockdown (data not shown), indicating that the
increased cell death was not due to classical activation
of apoptosis. Further flow cytometry analysis did not
show a perturbation in cell cycle composition or cellular
proliferation (PI and BrdU respectively, data not shown).
miR-10a knockdown was not found to have an influence
on the monocytic differentiation potential of OCI-
AML3 cells, with no significant difference in CD14,
CD15 or CD11b expression after 48 or 96 h of induc-
tion culture with 1,25-dihydroxyvitaminD3 (Additional
file 3: Figure S2).
Clonogenic potential of OCI-AML3 cells (Figure 2B)
demonstrated that knock-down in miR-10a levels
resulted in a reduced clonogenic capacity, with signifi-
cant reduction in colony number after 14 days (26.1%, p
< 0.05), with an associated trend towards smaller colony
size. These in vitro studies suggest miR10a has a pro-
survival role in the NPM1
mut-AML cell line.
Prediction and functional analysis of miR-10a targets
To identify genes potentially responsible for these func-
tional findings, we utilised the miRanda, PicTar and
TargetScan algorithms to predict mRNA targets of miR-
10a. This search yielded 976, 133 and 143 mRNA targets
respectively for a total 1071 unique targets. 44 genes
were simultaneously predicted by all three algorythms
(Table 1), and these will be referred to as stringently
predicted targets.
A list of genes that are known to be or could be
hypothesised to be dysregulated in AML was compiled,
and interrogated back to the permissively identified set
of potential miR-10a targets. Several resources were uti-
lised to compile this catalogue (as indicated in Table 2).
Advantage was also taken of published NPM1
mut-AML
gene expression profiling data [15-17] by compiling a
list of genes down-regulated in NPM1
mut-AML on the
microarrays. Correlating these genes with the 1071 pre-
dicted miR-10a targets revealed potential miR-10a gene
targets in each group as listed in Table 2. Of particular
note, the Sanger Cancer Census genes ARNT, BCL6 and
NR4A3, as well at the G.O.C. myeloid-related gene
NCOA6 (GO:0003099), each were also stringently pre-
dicted miR-10a targets of the 3 predictive algorithms.
With respect to the genes down-regulated in NPM1
mut-
AML, CENTD1, ITM2A, RARA and SPARC each possess
permissively identified miR-10a binding sites.
Figure 2 Functional effects of miR-10a. A.T r a n s f e c t i o no fO C I -
AML3 cells with anti-miR10a LNA resulted in 19% reduction in cell
count at 48 h as determined by MTS assay. B Assessment of
clonogenic potential found a significant decrease in mean colony
number (left), and a trend towards reduced Colony Size (right).
Values are normalised to Scrambled LNA Control. C A significant
increase in the number of Annexin-V positive events at 24 and 48 h.
D Cell cycle analysis demonstrated an increase in the proportion of
cells in the SubG1 fraction at 24 and 48 h post miR-10a knockdown.
Black bars = Scrambled LNA Control, White bars = Anti-miR10a LNA
transfected OCI-AML3 cells. E Confirmation of predicted miR-10a
gene targets by luciferase reporter assay: ARNT, GTFH1, ID4, KLF4,
MAPRE1, NR4A3, RB1CC1 and TFAP2C were confirmed to be miR-10a
repressible by this assay. White bars = miR-10a repression of 3’UTR
of the gene of interest, Black bars = miR10a repression of mutated
miR-10a binding site on the 3’UTR of the gene of interest. All values
were subject to normalisation to renilla luciferase activity of a non-
specific transfection control. Error bars denote SEM. For all
experiments n ≥ 3, statistical significance determined by Two-Tailed
T-Test. *p < 0.05, **p < 0.01, *** p < 0.001.
Table 1 miR-10a targets predicted by each of miRanda,
PicTar and TargetScan.
miR-10a gene targets predicted by miRanda, TargetScan and
PicTar
ACTG1 DOCK11 MAPRE1 SDC1
ANKRD12 DVL3 NARG1 SFRS1
ARNT ELAVL2 NCOA6 SLC25A1
ASXL1 FHL3 NCOR2 SLC38A2
BCL6 FXR2 NR4A3 SMAP1
BCL2L2 GRM3 NR5A2 SON
BTBD11 GTF2H1 PAFAH1B1 SVOP
BTBD14B HNRPK POPDC2 TFAP2C
CNNM4 HOXD10 PURB USF2
CTDSPL ID4 RAP2A WNK3
DAZAP1 IL1RAPL1 RB1CC1 ZMYND11
Of a total of unique 1071 mRNA targets predicted across the three algorithms,
44 were predicted to be targeted by miR-10a by all three
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Tables 1 and 2 for further analysis by reporter assay:
ARNT, CTDSPL, ID4, GTF2H1, KLF4, MAPRE1, NFIX,
NR4A3, NCOA6, NCOR2, RB1CC1, TFAP2C.E a c ho f
these genes has previously been demonstrated to be
involved in malignant processes through their down-reg-
ulation. Reporter assay confirmed A R N T ,G T F H 1 ,I D 4 ,
KLF4, MAPRE1, NR4A3, RB1CC1 and TFAP2c to be
miR-10a repressible genes, with further evidence of tar-
getting specificity provided by site directed mutagenesis
of the miR-10a binding site (Figure 2E).
Discussion
miR-10 family members are now implicated in the
malignant transformation across a range of tissues
through altered expression including breast cancer
[18-21], colon and oesophageal cancer [22,23], glioblas-
toma [24-26], hepatocellular carcinoma [27], melanoma
[18,28], neurofibromatosis [29], pancreatic cancer [30]
and urothelial carcinoma [31]. In murine models of
breast carcinoma miR-10b has been demonstrated to
have a crucial role in metastasis [19] with the pro-meta-
static effect repressible by systemic antisense inhibition
of miR-10b [21]. A similar role has also been demon-
strated in oesophageal cell lines [22]. miR-10a may have
ar o l ei ni n i t i a lo n c o g e n i ct r a n s f o r m a t i o ne v e n t se v i -
denced by the finding that miR-10a enhances the trans-
formation of NIH-3T3 cells by RAS-V12 [32]. Contrary
to these findings miR-10a is actually down-regulated in
chronic myeloid leukaemia (CML) CD34+ cells and
over-expression of miR-10a retards the growth of
KU812 cells (CML cell line) [33].
miR-10a first appeared in reference to AML when it
was individually selected along with miR-10b for
expression analysis in a cohort of AML cases [34], by
virtue of its residence within HOX clusters known to be
overexpressed in AML [35]. In a subsequent study, miR-
10a and miR-10b were found to be overexpressed (4.7
and 3.1 fold respectively) in NK-AML versus non NK-
AML [36,37]. Thus, miR-10 family expression appeared
to be reflective of the HOX over-expression characteris-
tic of NK-AML. The HOX expression profile itself
appears more specific to NPM1
mut-AML which has the
gene expression reminiscent of the haematopoietic stem
cell [15].
Garzon et al., (2008) also compared microRNA
expression between NPM1
mut-AML versus NPM1
WT-
AML. They found that a microRNA signature, domi-
nated by miR-10a, miR-10b and miR-100 over-expres-
sion in NPM1
mut-AML, was able to accurately
discriminate these AML subtypes. miR-10 family over-
expression was also noted in two subsequent studies
undertaking a similar comparison [38,39], but each uti-
lising the alternative platform of a multiplexed Taq-
Man
® MicroRNA Assay [40].
In each of the earlier publications miR-10a and miR-
10b were reported be co-overexpressed with a similar
FC. However, it may be difficult to confidently discrimi-
nate miR-10a from miR-10b expression, since they differ
at only a single nucleotide in the centre of the mature
microRNA outside the seed site. While miR-10a and
miR-10b share the same active 7 nucleotide seed site
and therefore a vastly overlapping target profile, each is
transcribed from distinct genomic locations and are
likely to be controlled by their own cis-regulatory net-
works. The current study utilised a stringent LNA-based
array which has a capacity to resolve miR-10a from
miR-10b expression with cross-hybridisation of less than
Table 2 miR-10a targets in pathways of potential relevance to AML.
Cancer Census Genes KEGG AML KEGG apoptosis KEGG cell cycle G.O.C. -myeloid related NPM1
mut-AML gene array
n = 366 n = 57 n = 62 n = 124 n = 80 n = 53
ARNT MLLT6 PIK3CA BAX CCNB3 KLF4 CENTD1
BCL6 NF2 RARA BCL2L11 CDK4 NCOA6 ITM2A
CDK4 NONO CASP9 CDKN2A PURB RARA
CREBBP NR4A3 FOXO3 CREBBP RASGRP4 SPARC
ERBB2 PDE4DIP IRAK4 ORC1L
ERCC3 PIK3CA ORC2L
FANCD2 PTEN ORDC5L
FOXO3 RARA
FUS RECQL4
HMGA2 SSX2
MLLT10 WRN
The genes listed in this table are those in each pathway that are also one of the 1071 permissively identified miR-10a targets. n refers to the number of genes in
each pathway interrogated for miR-10a targets. The genes linked to each of the heading in this table are listed in supplemental section. The final column refers
to genes that were down regulated in three mRNA gene expression profiling studies of NPM1
mut-AML [15-17]. The genes denoted in bold are those that were
also stringently identified by all 3 prediction programs. KEGG- Kyoto Encyclopaedia of Genes and Genomes. GOC.- Gene Ontology Consortium
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overexpressed in NPM1
mut-AML to a degree concordant
with the earlier studies (13.4 fold), miR-10b was much
more modestly DE (1.4 fold). Further to this, the expres-
sion ratio of miR-10a to miR-10b in the NPM1-mutated
s a m p l e sw a s5 4 : 1 .T h i ss u g g e s t st h a tm i R - 1 0 ai st h e
dominantly expressed family member in NPM1-AML
cases, which verifies Garzon et al., finding [41] and is
confirmed by a recent study by Ovchrenko et al. [42].
The normal physiological role of miR-10a is uncertain.
miR-10a is deeply conserved both with respect to its
sequence as well as its location within the HOXB cluster
[43,44]. The finding that several HOX genes including
HOXA1 [45], HOXA3 [46], HOXD4 [47] and HOXD10
[19] are repressible targets of miR-10 suggests that miR-
10 and HOX genes form an interconnected regulatory
network with an important role in embryonic develop-
ment. To date, minimal evidence exists to indicate that
miR-10 has a physiological role in normal haematopoi-
esis, substantiated only by the observation that miR-10a
is down-regulated as haematopoietic precursors mature
towards certain differentiated progeny, such as megakar-
yocytes [48] or lymphocytes [49].
To further evaluate the potential role of miR-10a over-
expression in NPM1
mut-AML, functional studies are
required to address the possibility the over-expression
may represent a passenger phenomenon consequent on
a permissive chromatin configuration encompassing the
HOXB locus. This is particularly important, since
NPM1
mut-AML is known to possess a HOX up-regu-
lated expression signature, although it is noted that
miR-10a is not overexpressed in MLL-deregulated
AMLs [38] which similarly upregulate HOX genes
[50,51].
We conducted functional studies in the NPM1
mut
OCI-AML3 cell line. We have demonstrated in this
study that knockdown of miR-10a overexpression in
these cells lead to a decreased cell count after 48 hours
in culture. Increased Annexin-V positive events but no
change in cell cycling or proliferation was noted at 24
and 48 h. However, Caspase-3 was not activated, which
suggests that the reduced cell survival occurs by a
mechanism other than classic apoptosis, such as necro-
sis, or via activation of Apoptosis-Inducible Factor lead-
ing to Caspase 3- independent apoptosis [52].
Interestingly, assessment of the clonogenic potential of
OCI-AML3 cells by growth on semi-solid media found
a decrease in the clonogenic potential of cells with miR-
10a knockdown, suggesting a possible role for miR-10a
in self renewal pathways.
We acknowledge that this study is constrained by the
current lack of NPM1
mut-AML cell lines, and future stu-
dies should determine the functional role of miR-10a by
manipulating its expression levels in primary cells from
AML patients, both with NPM1
wt and NPM1
mut,w h i c h
has its own technical challenges. The interaction between
miR-10a and NPM1
mut needs to be defined. Evaluation of
the leukaemogenic qualities of miR-10a, and its connec-
tion with the NPM
mut, in murine models might address
the unanswered issues raised by this study.
Prior to this study, only a short list of miR-10a repres-
sible targets had been experimentally confirmed includ-
ing Pbp1, RAN [32], USF2 [33] and the previously
mentioned HOX genes. We wished to identify miR-10a
gene targets which may explain the in vitro functional
findings induced by suppression of miR-10a. Particular
attention was paid to those genes that had previously
been shown to contribute to AML (or other malignan-
cies) by their down regulation. RB1CC1 is a tumour
suppressor and transcriptional promoter of key cell
cycle regulator retinoblastoma-1 [53] that has been
found to be inactivated in breast cancer by the intri-
guing means of truncational mutation [54]. Similarly,
TFAP2C transcriptionally activates p21 expression,
retards breast cancer cell growth, and decreases clono-
genic survival [55]. ID4 is a putative tumour suppressor
gene that is down-regulated by hypermethylation in
numerous cancers including ALL [56] and MDS [57].
KLF4 is not only a critical regulator of monocytic differ-
entiation [58], but has been shown to be pathologically
inactivated in medulloblastoma [59], and recently to
interact with miR-10b in transition to oesophageal can-
cer [22]. NR4A3 has previously been demonstrated to be
a critical tumor suppressor of myeloid leukemogenesis
[60] and possesses two 3’UTR seed matches to miR-10a,
which may increases capacity for translational repression
[61]. ARNT was examined, since down-regulation of the
AHR/ARNT pathway by epigenetic means in acute lym-
phoblastic leukaemia (ALL) [62] may be extrapolatable
to myeloid disease. GTF2H1 is a general transcription
factor involved in nucleotide excision repair, contribut-
ing to the maintenance of genomic stability [63].
MAPRE1 is involved in microtubular physiology and
maintenance of chromosomal stability [64], processes
often disturbed in AML. We have demonstrated that
these genes were shown to be the suppressible targets of
miR-10a by report assays and warrant further investiga-
tion. The mechanism of miR-10a over-expression is
unknown. It could be consequent upon copy number
amplification at the 17q21.32 locus where miR-10a
resides, although this was not seen by high density SNP
array (at 1 megabase resolution) in a cohort of AML
patients which included 14 cases of NPM1-AML [65].
miR-10a expression is influenced by the methylation sta-
tus of an upstream promoter [46], therefore analysis of
the methylation status and the broader epigenetic state
of the miR-10a locus in NPM1
mut-AML would be
helpful.
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We have shown that miR-10a is markedly over-
expressed in NPM1
mut-AML, and provided new evi-
dence that miR-10a is the dominantly expressed miR-10
family member in this class of AML. NPM1
mut OCI-
AML3 cell line shares high miR-10a expression with its
primary AML derivative. Knockdown of miR-10a in
these cells results in altered growth and cellular survival.
In view of these findings as well as those in other malig-
nancies, further evaluationo ft h er o l eo fm i R - 1 0 ai n
NPM1
mut AML is warranted.
Methods
Patient samples
T h ed i a g n o s t i cb o n em a r r o ws a m p l e so f2 8N K - A M L
cases with pre-Ficoll marrow blast counts of at least
50% were obtained after informed consent from the tis-
sue banks of our institute and the Australian Leukaemia
and Lymphoma Group Tissue Bank (demographic data
s h o w ni nA d d i t i o n a lf i l e4 :T a b l eS 2 ) .E i g h tn o r m a l
bone marrow samples were randomly obtained from our
institute’s tissue bank for comparison. To determine
NPM1 mutational status, the insertional hotspot was
RT-PCR amplified from complementary DNA using pre-
viously described primers [66] and directly sequenced
on the 3100XL from ABI 3100XL Genetic Analyser
using the reverse primer. 19/28 (68%) samples har-
boured NPM1
mut.
microRNA microarray and qRT-PCR
RNA was extracted from post-ficoll bone marron mono-
nuclear cells, and microRNA microarray (miRCURY
LNA microRNA probe set, Cat # 208010V8.1, Exiqon,
Vedbaek, Denmark) performed as previously described
in an overlapping cohort of patients [67]. The microar-
ray was performed at the Adelaide Microarray Facility.
In brief, 5 μg of total fluorescent labelled RNA was ana-
lysed in duplicate by two-sample (dual colour) competi-
tive hybridization with dye swap to control for labelling
efficiency. Slides were scanned at 10 μm resolution with
a Genepix 4000B Scanner (Molecular Devices, Sunny-
vale, CA). For the reference channel the total RNA from
normal patient samples were pooled in equal quantities.
For the bioinformatic microarray analysis, data were
processed as described [15] and [68]. We obtained the
fold change (FC) of microRNAs differentially expressed
(DE) between NPM1
mut and NPM1
wt-AML samples. For
this analysis we tested the null hypothesis that the dif-
ference in log-2 fold change for NPM1
mut and NPM1
wt
AML samples was 0 and the p-values were adjusted for
multiple comparisons. Hierarchical cluster analysis was
then performed using the probe sets identified to be sig-
nificantly DE and a heat map was generated.
To confirm miR-10a expression in primary samples
and comparison of expression in cell lines, 1 μgo ft o t a l
RNA was used for cDNA synthesis reaction using the
NCode microRNA first strand synthesis and qRT-PCR
kit (Invitrogen, USA). Quantitative real time polymerase
chain reaction (qRT-PCR) was performed using the Pla-
tinum Sybr Green Taq (Invitrogen, USA) and the Rotor-
gene RG-3000 thermocycler (Qiagen, Hilden, Germany).
RNU6b was used as the housekeeping microRNA. The
specific qRT-PCR primers were synthesised to order by
Integrated DNA Technologies (USA) as follows: miR-
10a (5-taccctgtagatccgaatttgtg-3) and RNU6b (5-
cgcttcggcagcacatatac-3). For functional cell line work,
microRNA expression was quantified by the TaqMan
miRNA assay (Applied Biosystems) as per manufac-
turer’s instructions, on the Rotorgene RG-3000 thermo-
cycler. All qPCR reactions were performed in duplicate
and RNU6b was also used as the housekeeping
microRNA.
miR-10a antisense repression and functional assays in
OCI-AML3 cells
The OCI-AML3 cell line is the only available AML cell
line bearing the NPM1 gene mutation (type A TCTG
duplication) and shares numerous phenotypic features
with primary NPM1
mut-AML samples (14). OCI-AML3
cells purchased from the DSMZ cell-line bank
(Braunschweig, Germany) were cultured in a-MEM
solution with 10% fetal bovine serum (GIBCO) once
their NPM1 mutational status was confirmed. Cells were
transfected with 50 nM anti-miR10a miRCURY LNA™
microRNA knockdown probes or negative control (Exi-
qon, Denmark) using Lipofectamine 2000 and Opti-
MEM (both from Invitrogen, USA) in antibiotic-free
media. Cells were maintained in a humidified incubator
at 37°C in 5% CO2. miR-10a knockdown was confirmed
by TaqMan qRT-PCR (Applied Biosystems) (Additional
file 3: Figure S2).
Cell growth and viability was analysed at 24 and 48 h
using the Promega CellTiter Aqueous One Solution Cell
Proliferation Assay (Promega) according to the manufac-
turer’s instructions, using Multiskan plate reader (Thermo
Labsystems). For this assay cells were plated in triplicate
for each transfection condition and time point. The MTS
absorbance reading at each time point was normalised to
a non-transfected lipofectamine-only control.
Cell cycle analysis was performed by exposing cells to
1 mL 1% TX-100, 50 μL 50 mg/mL propidium iodide
(PI) and 50 μL of 10 mg/mL RNAase A at 37°C for 30
min and analysed by the LSRII flow cytometer (BD
biosciences).
Apoptotic fractions of LNA-transfected OCI-AML3
cells were analysed by Annexin V/PI staining using the
Bryant et al. Molecular Cancer 2012, 11:8
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nogen) according to the manufacturer’si n s t r u c t i o n s .
Caspase-3 activation was measured using the plate-
based Caspase-Glo
® 3/7 Assay (Promega). Intracellular
activated caspase-3 was also directly measured by stain-
ing permeabilised cells (FACSperm, BD Biosciences)
with PE Rabbit Anti-Active Caspase-3 (BD Pharmingen).
Analysis was performed on FlowJo Software on at least
10,000 events acquired using a LSRII flow cytometer
(BD Biosciences).
Clonogenicity of OCI-AML3 cells treated with anti-
miR10a LNA or negative control was assayed by seeding
400 OCI-AML3 cells in 1 mL 1% MethoCell MC (in
RPMI with 10% FBS per 35 mm plate). Colony number
and size were scored microscopically (colony defined as
> 50 cells) using standard criteria after 14 days at 37°C
in 5% CO2.
miR-10a target prediction and validation
miRanda (union of http://microRNA.org and miRBase),
PicTar and TargetScan algorithms were utilised for the
in silico prediction of miR-10a mRNA targets. The
DAVID Functional Annotation Tool (http://david.abcc.
ncifcrf.gov/summary.jsp) was used to classify the genes
into ontologically-related terms and then examine for
potentially enriched terms [69]. To identify genes of
functional relevance in AML, several resources were uti-
lised. To capture potential oncogenes or tumour sup-
pressor genes, the Sanger Cancer Gene Census [70] was
sourced. Next, the following Kyoto Encyclopaedia of
Genes and Genomes (KEGG) Pathways [71] were con-
sidered: AML (hsa05221), apoptosis (hsa04210) and cell
cycle (hsa04110). To capture genes related to myeloid
differentiation, the following terms annotated by the
Gene Ontology Consortium (GOC) [72] were consid-
ered: haematopoiesis (GO:0030097), myeloid cell differ-
entiation (GO:0030099), myeloid leukocyte
differentiation (GO:0002573) and several terms related
to the regulation of these pathways (GO:0045637,
GO:0045638, GO:0045639, GO:0002761, GO:0002762
and GO:0002763). Finally advantage was taken of pub-
lished NPM1
mut-AML gene expression profiling data
[15-17] by compiling a list of genes down-regulated in
NPM1
mut-AML on the microarrays.
Bioinformatically predicted miR-10a binding sites were
analysed by luciferase reporter assay as described in
detail previously [67]. To confirm the specificity of the
3’UTR binding site, at least 3 bases of the relevant seed
region in the pMIR.3UTR constructs were mutated by
site-directed mutagenesis (Stratagene) or by a PCR-
based technique and the assay was repeated using the
mutated construct.
Additional material
Additional file 1: Table S1. List of significantly (p < .05)
differentially expressed probes on microarray comparison of NK-
AML samples versus normal bone marrow. Only those microRNAs
with a FC of ≥ 2 in either direction were included in this table. There
were 26 overexpressed probes and 11 under expressed probes in NK-
AML versus normal BM. The microRNAs depicted in bold represent
proprietary miRPlusTM probe whose sequences have subsequently been
annotated on miRBase. Those probes denoted as miRPlusTM have not
been further annotated by the release of miRBase release 15.
Additional file 2: Figure S1. Confirmation of miR-10a knockdown by
anti-10a LNA. A. miR-10a expression 24 h after transfection with Exiqon
(LNA) anti-microRNA ASO was assayed by TaqMan microRNA qRT-PCR.
RNU6b was used as the reference gene. MiR-10a expression was
normalised to that of cells transfected with 100 nM of the non-targeting
control specific to each chemistry, with comparison made to
untransfected cells The graph depicts the mean miR-10a relative
expression of individual experiments for Ambion Anti-miRs (n = 4) and
Exiqon LNAs (n = 3), +/-SEM (of fold change values). B. Hela cells were
pre-treated with either pcDNA.10a (miR-10a overexpressing plasmid), 30
nM of Pre-miR-10a or were not pre-treated. After 6 h, transfection media
was removed and cells washed with PBS. Cells were then transfected
with pMIR.HOXA1/pRLCMV and 50 nM of either anti-10a LNA or LNA
Control A. After 24 h, Dual Luciferase Assay (Promega) was performed in
triplicate. The whole experiment was repeated 5 times. The graph
depicts the mean luciferase values for anti-10a LNA treated cells
compared to the LNA Control A treated cells (+/-SEM), with the control
values corrected to 100. The statistical analysis consists of Student’s t-test
(paired). NS: not significant; * 0.01 < p < 0.05; ** 0.001 < p < 0.01.
Additional file 3: Figure S2. Monocytic differentiation of OCI-AML3
cells is not affected by miR-10a knockdown. 1,25-dihydroxyvitaminD3
(VitD3) was used to induce monocytic differentiation of OCI-AML3 cells
over a 96 h period. A. Morphological analysis (Wright Stain) of cytospin
samples of OCI-AML3 cells treated with VitD3 demonstrated no
observable differences between SCRAM control transfected and anti-
miR10a LNA transfected groups. B. Phenotype analysis of CD14 C. CD15
and D. CD11b expression by flow cytometry did not detect a statistically
significant difference between SCRAM control or anti-miR10a LNA groups
at 48 h or 96 h post, regardless if cells were treated with VitD3 (+) or did
not receive treatment (-). N = 3.
Additional file 4: Table S2. Patient demographics and AML blast
characteristics.
Abbreviations
AML: Acute myeloid leukaemia; NPM1: Nucleophosmin-1; NK: Normal
karyotype; LNA: Locked nucleic acid.
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